Abiopharma

🔍 Nayyar Nayaki R (Executive)

Company: Corteva, Inc. (CTVA)

Report Date: 2026-04-30

Detailed Transactions and Holdings:

• Acquired 401 shares of Common Stock at $81.01 per share (Direct)
  Date: 2026-04-30 | Code: A | equity_swap_involved: false | shares_owned_after: 36,254.58 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Represents stock units acquired pursuant to the Issuer's Stock Accumulation and Deferred Compensation Plan for Directors under which non-employee directors may elect to defer the payment of all or a specified portion of their cash compensation to be settled in CTVA common stock on a one-for-one basis on a future date selected by the Reporting Person at the time of his or her deferral election. Cash compensation deferred in the form of stock units is calculated based on the closing price of CTVA common stock on the date the cash compensation would have otherwise been payable.